Earnings · China A-shares
Chengdu Olymvax Biopharmaceuticals Inc. Class A (688319) earnings
Chengdu Olymvax Biopharmaceuticals Inc. Class A published its Q3 report on 2026-10-29: net profit -114.33% year on year, -57.86% excluding one-off items. Wave Radar's earnings-quality score is 59 of 100 (Questionable). The stock moved +6.34% in the 3 trading days after the report.
- Report
- Q3 report
- Published
- 2026-10-29
- Period end
- 2026-09-30
- Net profit YoY
- -114.33%
- Excl. one-offs YoY
- -57.86%
- Result
- Bad / loss
- Quality score
- 59
- Quality
- Questionable
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | +3.42% | — |
| 3 days | +6.34% | — |
| 7 days | +7.99% | — |
| 14 days | -2.75% | — |
Report history
Over the last 8 reports, net profit grew year on year in 6 of them. The stock rose in the 3 trading days after 6 of 8 reports (average +4.92%).
| Report | Published | Net profit | Profit YoY | Excl. one-offs YoY | Revenue YoY | EPS | ROE | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3 report | 2026-10-30 | -¥6.80M | -114.33% | -57.86% | +18.15% | -0.02 | -0.76% | +6.34% | — | — |
| 2026 interim report | 2026-08-18 | -¥32.87M | -349.09% | — | +18.14% | -0.08 | -3.71% | +3.59% | +9.23% | +17.19% |
| 2026 Q1 report | 2026-04-30 | ¥27.19M | +484.36% | +311.18% | +80.37% | 0.07 | 2.96% | +16.90% | +20.74% | +18.69% |
| 2025 annual report | 2026-03-31 | ¥22.26M | +7.24% | -11.38% | +19.58% | 0.05 | 2.38% | +1.54% | +31.47% | +23.05% |
| 2025 Q3 report | 2025-10-30 | ¥47.48M | +1079.36% | +12157.47% | +31.11% | 0.12 | 5.02% | -2.12% | +8.36% | +13.11% |
| 2025 interim report | 2025-08-29 | ¥13.20M | +147.22% | +124.20% | +35.17% | 0.03 | 1.42% | -1.40% | -21.76% | -23.03% |
| 2025 Q1 report | 2025-04-26 | -¥7.07M | +72.79% | +60.40% | +23.58% | -0.02 | -0.77% | +2.57% | +7.64% | +4.39% |
| 2024 annual report | 2025-03-29 | ¥20.76M | +18.24% | +230.01% | +18.69% | 0.05 | 2.24% | +11.91% | +5.26% | +6.82% |
The last 8 reports. Net profit is attributable to shareholders and year-to-date (a Q3 report covers the first nine months). Moves count trading days from the first tradeable session after publication; "30d vs index" is the excess return over CSI 300.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.